Literature DB >> 12087006

Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects.

Michael Hummel1, Ezio Bonifacio, Heike E Naserke, Anette G Ziegler.   

Abstract

OBJECTIVE: Removal of the dietary wheat protein gluten protects against autoimmune diabetes in animal models. Furthermore, elimination of dietary gluten reduces the frequency of type 1 diabetes in patients with celiac disease. Herein we test the hypothesis that gluten is the driving antigen for type 1 diabetes-associated islet autoimmunity. RESEARCH DESIGN AND METHODS: Seven autoantibody-positive, first-degree relatives of patients with type 1 diabetes were placed on a gluten-free diet for 12 months followed by gluten reexposure for 12 months. Gliadin antibodies as well as the diabetes-related antibodies insulin autoantibody (IAA), GAD antibody (GADA), and tyrosin phosphatase IA2 antibody (IA-2A) were measured every 3 months; oral glucose tolerance tests were performed every 6 months. Changes in autoantibody titers were compared with those observed in a matched historical cohort.
RESULTS: A reduction in IgG gliadin antibody titers was observed during the gluten-free period, but titers of diabetes-associated autoantibodies changed independently of gluten exposure. Type 1 diabetes-associated islet autoantibody levels at the end of the gluten-free diet period were not significantly different from those before commencement of the diet (P = 0.2) or at the end of the gluten reexposure period (P = 0.4). Changes in individual subjects were identified, but no differences were noted between the gluten-free and the gluten re-exposure periods, and the changes were similar to those observed in the historical control cohort (P = 1.0). Major titer reductions (>50%) in the gluten-free period were observed in only one subject for all antibodies. Type 1 diabetes developed in this subject and in a second subject during the gluten reexposure period.
CONCLUSIONS: The findings do not support the hypothesis that gluten is a driving antigen in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087006     DOI: 10.2337/diacare.25.7.1111

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  15 in total

Review 1.  Environmental triggers of type 1 diabetes.

Authors:  Mikael Knip; Olli Simell
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Genes mediating environment interactions in type 1 diabetes.

Authors:  Erik Biros; Margaret A Jordan; Alan G Baxter
Journal:  Rev Diabet Stud       Date:  2006-02-10

Review 3.  Early life origin of type 1 diabetes.

Authors:  Mikael Knip; Kristiina Luopajärvi; Taina Härkönen
Journal:  Semin Immunopathol       Date:  2017-11-23       Impact factor: 9.623

Review 4.  Environmental risk factors for type 1 diabetes.

Authors:  Marian Rewers; Johnny Ludvigsson
Journal:  Lancet       Date:  2016-06-04       Impact factor: 79.321

5.  Gluten Intake and Risk of Islet Autoimmunity and Progression to Type 1 Diabetes in Children at Increased Risk of the Disease: The Diabetes Autoimmunity Study in the Young (DAISY).

Authors:  Nicolai A Lund-Blix; Fran Dong; Karl Mårild; Jennifer Seifert; Anna E Barón; Kathleen C Waugh; Geir Joner; Ketil Størdal; German Tapia; Lars C Stene; Randi K Johnson; Marian J Rewers; Jill M Norris
Journal:  Diabetes Care       Date:  2019-02-22       Impact factor: 19.112

Review 6.  Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions.

Authors:  Jennifer M Barker; Edwin Liu
Journal:  Adv Pediatr       Date:  2008

7.  Elimination of dietary gluten and development of type 1 diabetes in high risk subjects.

Authors:  Martin Füchtenbusch; Anette-G Ziegler; Michael Hummel
Journal:  Rev Diabet Stud       Date:  2004-05-10

Review 8.  The role for gut permeability in the pathogenesis of type 1 diabetes--a solid or leaky concept?

Authors:  Xia Li; Mark A Atkinson
Journal:  Pediatr Diabetes       Date:  2015-08-13       Impact factor: 4.866

Review 9.  Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Authors:  T Staeva-Vieira; M Peakman; M von Herrath
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 10.  Progress in immune-based therapies for type 1 diabetes.

Authors:  M von Herrath; M Peakman; B Roep
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.